SCHEMBL3015834

SCHEMBL3015834

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4Cl)CC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 6/20 0.48
CTSS P25774 4/20 0.48
SMN1; SMN2 Q16637 9/20 0.48
L3MBTL1 Q9Y468 5/20 0.48
ALDH1A1 P00352 4/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
LMNA P02545 6/20 0.45
MAPT P10636 5/20 0.45
HTT P42858 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
AR P10275 2/20 0.43
TSHR P16473 2/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002078 0.93 MAPK1 (0.47) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3010403 0.91 SMN1; SMN2 (0.48) MAPK1SMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3008170 0.91 MAPK1 (0.50) MAPK1SMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3014430 0.90 SMN1; SMN2 (0.52) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3008323 0.90 SMN1; SMN2 (0.52) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3018188 0.89 SMN1; SMN2 (0.47) MAPK1SMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3010502 0.89 CTSS (0.48) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3015211 0.88 MAPK1 (0.49) MAPK1SMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3013324 0.88 CTSS (0.52) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3011818 0.88 CTSS (0.46) MAPK1CTSSSMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885CTSS 106/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.